NCCN Guidelines Updated to Include PSMA-PET Imaging
Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 14 September 2021. Telix welcomes the updated NCCN Guidelines® for prostate cancer, which includes PSMA PET imaging modalities, including Ga-68 PSMA-11.
Telix welcomes the updated National Comprehensive Cancer Network® (NCCN) Guidelines® for prostate cancer, which includes prostate specific membrane antigen (PSMA) positron emission tomography (PET) imaging modalities, including Ga-68 PSMA-11.
Telix’s New Drug Application (NDA) for investigational imaging product Illuccix® (Kit for the preparation of 68Ga-PSMA-11 injection) is in the late stages of review by the United States Food and Drug Administration. The NCCN Guidelines® are a recognised standard for clinical direction and policy in cancer care and are used widely by clinicians and payors.
The NCCN Panel has recognised the increased sensitivity and specificity of PSMA-PET tracers for detecting micrometastatic disease compared to conventional imaging (CT, MRI) at both initial staging and biochemical recurrence. The updated guidelines state that the NCCN Panel does not feel that conventional imaging is a necessary prerequisite to PSMA-PET and that PSMA-PET/CT or PSMA-PET/MRI can serve as equally effective, if not more effective front-line imaging tools for these patients. The updated guidelines now include Ga-68 PSMA-11 PET/CT to be considered as an alternative to standard imaging of bone and soft tissue.
Dr Colin Hayward, Chief Medical Officer of Telix said, “This is an important change to the guidelines which will influence a shift in clinical practice to consider PSMA-PET imaging as an alternative to standard imaging of bone and soft tissue for the detection of unfavourable intermediate, high and very high risk as well as recurrent prostate cancer.”
“The NCCN guidelines are considered a global standard to guide oncology practice and reimbursement. The inclusion of PSMA-PET, including with Ga-68, the isotope used in our investigational imaging product Illuccix® further signals the emergence of PSMA-PET imaging as a state-of-the-art imaging modality.”
Dr Oliver Sartor, Medical Director at Tulane Cancer Center said, “The updated guidelines will encourage clinicians to use PSMA-PET as a primary imaging modality in patients and will deliver the benefit of a more streamlined approach. We look forward to having access to this functional form of imaging as new products come into the market.”
To read the full ASX disclosure please click here.
To return to Telix’s homepage please click here.
Telix and University of Queensland-led Consortium Awarded $5M Australian Research Council (ARC) Grant
Melbourne – 8 August 2022. Telix and University of Queensland-led Consortium Awarded $5M Australian Research Council (ARC) Grant
Telix 1H 2022 Financial Results and Company Update Investor Call
Melbourne (Australia) – 4 August 2022. Telix to hold investor conference call to present 1H 2022 financial results and Company...
APAC Report: Regulatory Progress for Prostate and Kidney Cancer Imaging
Melbourne (Australia) – 2 August 2022. Telix announces Regulatory Progress in the APAC Operating Region for Prostate and Kidney Cancer...